The European Commission has granted marketing authorization to Sanofi and GSK for VidPrevtyn Beta, an adjuvanted protein-based COVID-19 booster vaccine. This approval follows a positive opinion from the European Medicines Agency (EMA) and is based on data demonstrating the vaccine's efficacy as a booster against multiple SARS-CoV-2 variants.

VidPrevtyn Beta is indicated for use as a booster in adults who have previously completed a primary COVID-19 vaccination series. The vaccine leverages a beta variant antigen and GSK's pandemic adjuvant technology, aiming to broaden immune response against circulating variants.

This development provides healthcare professionals across Europe with an additional option for COVID-19 booster vaccination, supporting ongoing public health efforts to manage the pandemic. For more information, visit Sanofi's official announcement.